245 related articles for article (PubMed ID: 16642541)
1. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
[TBL] [Abstract][Full Text] [Related]
3. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.
Gex-Fabry M; Rudaz S; Balant-Gorgia AE; Brachet A; Veuthey JL; Balant LP; Bertschy G
Eur J Clin Pharmacol; 2002 Aug; 58(5):323-31. PubMed ID: 12185556
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.
Allard P; Gram L; Timdahl K; Behnke K; Hanson M; Søgaard J
Int J Geriatr Psychiatry; 2004 Dec; 19(12):1123-30. PubMed ID: 15526307
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
[TBL] [Abstract][Full Text] [Related]
6. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
9. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
[TBL] [Abstract][Full Text] [Related]
11. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
14. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
[TBL] [Abstract][Full Text] [Related]
15. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA
J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189
[TBL] [Abstract][Full Text] [Related]
16. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2D6 genotype variation and venlafaxine dosage.
McAlpine DE; O'Kane DJ; Black JL; Mrazek DA
Mayo Clin Proc; 2007 Sep; 82(9):1065-8. PubMed ID: 17803873
[TBL] [Abstract][Full Text] [Related]
19. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
20. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
